Matt Sik's questions to Myriad Genetics Inc (MYGN) leadership • Q1 2025
Question
Matt Sik of Goldman Sachs asked for more specifics on the sources of the $25 million in operating expense reductions in the revised guidance. He also inquired about the remaining potential for improvement in Revenue Cycle Management (RCM).
Answer
CEO Samraat Raha and CFO Scott Leffler explained that OpEx savings are being realized from discretionary areas like hiring controls, travel, and consulting fees, while protecting strategic investments in R&D and commercial operations. Regarding RCM, Scott Leffler noted that despite improving the no-pay rate in 2024, a significant opportunity remains to capture revenue from the large volume of unpaid claims, and investments in this area continue.